HRVSF - Harvest Health & Recreation Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
-0.1506 (-4.77%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close3.1600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.9421 - 3.2800
52 Week Range2.0300 - 10.8500
Avg. Volume318,898
Market Cap875.32M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5390
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.49
  • PR Newswire

    Falcon International Corp. Responds To Complaint Filed By Harvest Health & Recreation, Inc. And Affiliates

    Falcon International Corp. announced that on Friday, January 17, 2020 it moved to dismiss the recent complaint filed against it by Harvest Health & Recreation, Inc. (CSE: HARV, OTCQX: HRVSF) and certain of its affiliates for lack of jurisdiction. As more fully set forth in the motion, Falcon has the right pursuant to the terms and conditions of its heavily negotiated merger agreement to require Harvest to pay Falcon a cash breakup fee in the amount of US$50.0 million. In addition, amounts previously funded by Harvest to Falcon are convertible into Falcon equity at Harvest's or Falcon's option and, accordingly, are unlikely to be paid. Falcon expects that it will prevail in defending the matters set forth in Harvest's complaint and that it will be successful in enforcing its rights against Harvest as set forth in the merger agreement and related documents.

  • CNW Group

    Harvest Health & Recreation Enters into Strategic Relationship with First Provisioning Center in Michigan

    PHOENIX , Jan. 20, 2020 /CNW/ -- Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) ("Harvest"), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today announced a strategic relationship with Harvest of Battle Creek , a new provisioning center in Michigan . The new partnership continues Harvest's successful expansion into new markets and demonstrates the company's commitment to increasing patients' and customers' access to best-in-class medical marijuana experiences.

  • Market Exclusive

    Harvest Health & Recreation to Acquire Interurban

    Harvest Health & Recreation (CSE: HARV) (OTCQX: HRVSF) has announced that it is moving into the next stage in the process to acquire Interurban Capital Group, the owner and operator of Have a Heart CC. The parties have reached a stage that requires disclosure, according to Harvest statement. Preliminary terms suggests an acquisition price of approximately […]The post Harvest Health & Recreation to Acquire Interurban appeared first on Market Exclusive.

  • Benzinga

    Harvest Health Weighs $87.5M Purchase Of Cannabis Retailer Have A Heart

    Harvest Health & Recreation Inc (CSE: HARV) (OTC: HRVSF ), a vertically integrated cannabis company, said Monday that it is in negotiations to acquire Interurban Capital Group Inc, the owner and operator ...

  • CNW Group

    Harvest Files Suit Against Falcon International, Inc.

    PHOENIX , Jan. 7, 2020 /CNW/ -- Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) ("Harvest"), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today announced that yesterday Harvest filed suit against Falcon International, Inc. ("Falcon") requesting termination and rescission of the Merger Agreement ("Transaction") and return of money Harvest paid to Falcon under the Merger Agreement. As detailed in the Complaint, filed in U.S. Federal Court, District of Arizona , Harvest alleges that Falcon has failed to meet its legal obligations in multiple ways, including the failure to provide auditable financial records, which precludes Harvest from moving forward with the Transaction.

  • PR Newswire

    Harvest Announces Potential Acquisition of Interurban Capital Group

    Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) ("Harvest"), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today announced that negotiations to acquire Interurban Capital Group, Inc., the owner and operator of Have a Heart CC ("Have a Heart"), have reached a stage that require disclosure. Preliminary terms contemplate an acquisition price of approximately $87.5 million in Harvest stock and assumption of debt convertible into 205,594 multiple voting shares of Harvest stock, subject to applicable Canadian securities laws. Have a Heart assets include 11 operating dispensaries in California, Washington and Iowa and licenses for seven retail locations in California.

  • CNW Group

    Harvest Health & Recreation Inc. Welcomes Ron Goodson as Chief Operating Officer

    PHOENIX , Jan. 6, 2020 /CNW/ -- Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) ("Harvest"), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., has hired Ron Goodson as Chief Operating Officer ("COO"), effective immediately. An executive with more than three decades in the food, beverage and consumer goods industry, Goodson will enhance Harvest's capabilities to scale its operations in key markets nationwide and to drive profitable revenue goals. Goodson will report to Harvest CEO Steve White and replaces outgoing COO John Cochran .

  • 3 “Strong Buy” Cannabis Stocks Set to Benefit From Mergers

    3 “Strong Buy” Cannabis Stocks Set to Benefit From Mergers

    The cannabis sector has run into major liquidity issues with the lack of access to the banking system in the U.S. and market issues in Canada. In the process, the market has seen a substantial decline in mergers with a shift in deals towards stock-for-stock ones. Several companies set to close big U.S. deals could stand out in a sector where competitors can’t merge to compete on scale.According to Viridian Capital Advisors, the cannabis sector ended 2019 at a crawl. Capital raises were near non-existent with only 2 for the week ending December 13 and no M&A activity during the week. In the prior year period, 7 capital raises occurred.For the year, 2019 cannabis M&A activity saw 293 deals down from 311 in 2018. As the below chart shows, M&A activity came to a near stop in the last few months. Earlier in the year, 10 deals were happening on a weekly basis.In a lot of cases, deals formed in 2019 were either modified to eliminate cash requirements or completely canceled. Some high-profile deals are still set to close to create leaders in the U.S. multi-state (MSO) operator space. With the opening of recreational cannabis in Illinois on January 1 and potentially additional states in 2020, several companies are set to stand apart from the market.We’ve delved into three companies set to benefit from closing large-scale mergers right as the market freezes up. According to TipRanks’ stock screener, the trio have earned a Strong Buy consensus rating from the analyst community over the past three months. Let's take a closer look:Curaleaf Holdings (CURLF)Curaleaf is still poised to become the biggest cannabis company in the world. The company remains set to close both the Select and Grassroots deals in early 2020 to set Curaleaf up for over $1 billion in pro-forma sales.The Select deal is set to close in early January setting up some positive sentiment on the stock as Curaleaf finally gets to move forward with integration. In addition, closing the deal will provide more confidence on the Grassroots deal, a deal that provides access to the potentially lucrative Illinois market.Select provides the company with access to the California wholesale market with a leading cannabis brand. The deal was modified due to market conditions placing a part of deal based on the obtainment of revenue goals.The Grassroots deal is expected to close in Q1. The deal requires a cash payment of $75 million, 109.2 million shares based on the current stock price of $6.25.In total, Curaleaf expects a business with access to 19 states with 71 retail locations open, 26 processing facilities and 21 cultivation facilities operational. The company is heading towards 131 stores along with a large wholesale distribution network with the Select brand.The stock has 464 million shares outstanding now and nearly 670 million when the two major deals are complete. The updated share count assumes 40.5 million shares will be payable to Select shareholders under the amended agreement. At the current stock price of $6.25, Curaleaf will have a fully diluted market valuation of only $4.2 billion. The stock trades at only 2.8x 2021 sales estimates of $1.5 billion.Curaleaf has earned one of the best analyst consensus ratings on the Street. Out of 8 analysts polled by TipRanks in the last 3 months, seven are bullish on Curaleaf’s prospects, with just one on the sidelines, highlighting a strong bullish backing here. With a healthy return potential of 72%, the stock’s consensus target price stands at $10.43. (See Curaleaf's price targets and analyst ratings on TipRanks)Cresco Labs (CRLBF)Cresco Labs has had some of the most dramatic shift in their acquisition plans during 2019. The company originally planned mergers with Origin House and VidaCann, but the later was canceled due to the cash component of the deal. In the process, Cresco Labs has already closed a deal to acquire the Valley Agriceutials, LLC in New York.Even the Origin House deal was modified to allow Origin House to sell 9.7 million shares at C$4.08 in order to raise gross proceeds of C$39.6 million before the deal closes. The new deal is expected to close in mid-January at an updated ratio of 0.8428 shares of Cresco Labs for each share of Origin House.In October, the company closed a deal for Valley Agriceuticals providing one of the 10 vertically integrated cannabis business licenses in the State of New York. Cresco Labs can operate one cultivation facility and four dispensaries in the state set to grow to $500 million by 2022.In addition, the Tryke Companies deal announced in September has already passed HSR Act waiting period. The company is set to close this deal in early 2020 providing access to the Arizona and Nevada markets with a combined $1.7 billion in annual sales. The deal cost $282.5 million ($55.0 million in cash) and Tryke generated $70.4 million in revenues back in 2018.Analysts estimates 2020 sales of $554 million with 2021 reaching $866 million.Overall, this cannabis player stands as a 'Strong Buy' name among Wall Street analysts. In the last three months, Cresco Labs has won six bullish recommendations. With a return potential of close to 90%, the stock's consensus price target lands at $12.23. (See Cresco Labs' stock-price forecast and analyst ratings)Harvest Health & Recreation (HRVSF)Harvest Health & Recreation is in a similar position as the other U.S MSOs. The company has several pending deals and recently renegotiated one of the deals to reduce cash payments.The biggest deal is for Verano Holdings that passed the HSR Act waiting period on December 4. In addition, the company has pending deals with Falcon, Franklin Labs and Devine Holdings after closing acquisitions with Leaf Life and Urban Greenhouse. The end result was Harvest Health only reporting Q3 revenues of $33.2 million with pro forma revenues of an incredible $95.0 million once including the numbers from all of these deals.After closing the deals, Harvest Health expects to have over 210 facilities including 130 retail locations with more than 1,700 employees across 18 states and territories. Harvest Health has a fully diluted market valuation of under $1.5 billion once the pending M&A deals are done. The large cannabis company will have ~487 million shares outstanding.The full picture of the company is probably not represented in the market mindset now. Harvest Health is still forecasting 2020 revenues between $700 million and $1,000 million with at least 20% EBITDA margins.Judging from the consensus breakdown, it has been relatively quiet when it comes to the analyst activity. Over the last three months, only 3 analysts have reviewed the cannabis stock. Three of which, however, were bullish, making the consensus a Strong Buy. On top of this, the $10.08 average price target puts the upside potential at 216%. (See Harvest Health's price targets and analyst ratings on TipRanks)

  • Benzinga

    Harvest Health & Recreation Buys Nevada Grow Facility From MJardin Group In $35M Deal

    Multistate operator Harvest Health & Recreation Inc (OTC: HRVSF ) said Thursday that it has agreed to purchase a 32,000-square-foot subruban Las Vegas cultivation facility from the Cheyenne, Nevada-based ...

  • PR Newswire

    Harvest Health & Recreation Inc. Agrees to Acquire MJardin Group Asset to Expand Cultivation Capacity in Nevada

    Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) ("Harvest"), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today announced the signing of a definitive agreement to acquire a 32,000 square foot cultivation facility in Cheyenne, Nevada, a Las Vegas suburb, from MJardin Group ("MJardin"), a cannabis management platform with extensive experience in cultivation, processing, distribution and retail. This purchase price for the transaction is $35 million and is being financed by an existing Harvest lender. The amount of $30 million was funded on December 31, 2019 and the balance of $5 million is due upon the closing of the acquisition. The transaction will provide Harvest with a best-in-class operating asset, enhancing the company's ability to achieve profitability. The completion of the acquisition is subject to, among other things, the receipt of regulatory approvals and the satisfaction or waiver of closing conditions customary for a transaction of this nature.

  • PR Newswire

    Harvest Adding Senior Leadership Experienced in Capital Markets and Fundraising

    Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) ("Harvest"), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today announced two additions to the senior leadership team. Scott Atkison, a seasoned business and cannabis operator, joins Harvest as Co-Executive Chairman in a non-board capacity. Daniel Reiner, a seasoned business leader and serial investor joins as a special advisor to Harvest's board. Both Atkison and Reiner will bring valuable expertise, networks and skills to Harvest as it focuses on new capital markets and fundraising in 2020.

  • CNW Group

    Harvest Expands Operations in Maryland with AmediCanna Management Services Agreement

    PHOENIX , Dec. 19, 2019 /CNW/ -- Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) ("Harvest"), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today signed a state-approved management services agreement with Maryland dispensary AmediCanna Dispensary, LLC ("AmediCanna"), located in Halethorpe, Maryland . The agreement provides Harvest with the right to operate the retail location and the option to acquire the license in the future upon state approval. This agreement advances Harvest's goal to efficiently scale while also bringing trusted cannabis experiences to customers nationwide.

  • Market Exclusive

    Harvest Health Appoints Two CEOs to Board

    Harvest Health & Recreation (CSE: HARV) (OTCQX: HRVSF) has announced the appointment of Ana Dutra and Eula Adams to its board of directors, effective immediately. Dutra is the CEO of Mandala Global Advisors, while Adams is CEO of Neuromonics Corp. "The addition of these two directors complements our vision to improve lives through the goodness […]The post Harvest Health Appoints Two CEOs to Board appeared first on Market Exclusive.

  • Harvest Health & Recreation Announces National Roll Out of Award-Winning Products from Evolab
    PR Newswire

    Harvest Health & Recreation Announces National Roll Out of Award-Winning Products from Evolab

    Harvest Health & Recreation, Inc. (CSE: HARV, OTCQX: HRVSF) ("Harvest"), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today announced the availability of a series of advanced, high-quality vaporizers at Harvest stores and select retailers in Arizona, Colorado and Maryland. The product line, from award-winning brand Evolab includes Chroma™, Alchemy™ and Delta 8, all of which utilize a distillation process resulting in an extract that is 100% cannabis-derived, free from cutting agents using instrument grade CO2 — considered a clean extraction method.

  • Benzinga

    Benzinga Heads To Miami For The First Cannabis Capital Conference Of 2020

    DETROIT — The premier gathering of cannabis entrepreneurs and investors in North America, the Benzinga Cannabis Capital Conference , is heading to Miami in 2020 for its sixth installment. The conference, ...

  • 5 Under-the-Radar Marijuana Stocks With Over 100% Upside

    5 Under-the-Radar Marijuana Stocks With Over 100% Upside

    Is the cannabis sector about to light up? Following the U.S. House Judiciary Committee's monumental decision to approve the Marijuana Opportunity Reinvestment and Expungement (MORE) Act on Nov. 20, investor focus has locked in on this area of the market.With the passage of this legislation, the cannabis industry takes a huge leap forward as the bill would remove marijuana from the Schedule I list of controlled substances as well as decriminalize it at the federal level. However, the bill wouldn't legalize the substance."Today's vote marks a turning point for federal cannabis policy, and is truly a sign that prohibition's days are numbered," executive director of the National Cannabis Industry Association Aaron Smith stated.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs 65% of Americans support the legalization of marijuana, according to a CBS News polling conducted in April, is now the time to snap up marijuana stocks? Wall Street seems to be advocating that investors do just that.Analysts remind investors to focus on the names poised to soar through 2020. The most compelling investments can be the names making moves behind the scenes. * 7 Exciting Biotech Stocks to Buy Now Using TipRanks' Stock Screener, I was able to pinpoint five marijuana stocks that have been flying under the radar. While largely avoiding the spotlight, these names boast upside potential that demands attention. I'm talking in the triple digits.Let's dive right in. OrganiGram (OGI) Source: Shutterstock OrganiGram (NASDAQ:OGI) is feeling the heat following its fiscal fourth-quarter earnings release.During the quarter, the company posted a bottom-line miss. The net loss came in at 22.5 million CAD. The consensus estimate had pointed to a loss of only 1 cent per share. This news was even more concerning as it followed up a profit of 18.2 million CAD, or 12 cents per share, in the year-ago quarter. Management noted that an insufficient retail network as well as slower-than-expected store openings in Ontario were partly to blame for the disappointing performance.That being said, OGI still has a lot going for it. The cannabis name operates out of a single facility located in New Brunswick, making it more efficient than some of its peers. Rather than opening giant new facilities, it has placed a significant focus on producing higher-quality cannabis. Not to mention the company has received licensing approval for 17 new growing rooms, which should bring annual production capacity to 76,000 kilograms.Paradigm analyst Corey Hammill believes that this puts the company in a position to gain. OGI also stands to benefit from Cannabis 2.0, the legalization of cannabis derivative products in Canada. To this end, he reiterated his "buy" rating and $3.95 price target.Looking at the consensus breakdown, six buys and three holds add up to a "moderate buy." Its $6 average price target is the real star of the show here, though, indicating upside potential of 136%.See the OGI stock analysis. Harvest Health & Recreation (HRVSF) Source: Shutterstock "Not ideal" is the phrase being tossed around when describing Harvest Health & Recreation's (OTCMKTS:HRVSF) performance in its most recent quarter. The Arizona-based marijuana name announced its financial results for the third quarter on Nov. 20. The company reported that total revenue reached $33.2 million, up a whopping 197% from the prior-year quarter. However, adjusted EBITDA came in at a loss of $11 million, with both this figure and revenue falling below estimates.Nonetheless, Beacon's Russell Stanley reminds investors that there were positive takeaways. "We attribute the selling pressure on the stock to uncertainty with respect to Harvest's balance sheet and access to capital, and based on management's comments during this morning's conference call, we believe the company's asset base can support the additional debt required to accelerate growth," he explained.On top of this, Stanley argues that HRVSF is trading at a discount compared to other players. And several upcoming catalysts could catapult shares higher. While keeping the bullish call, he did reduce the price target to $11.29. Even at this lower target, the analyst thinks shares could skyrocket 341% in the next 12 months.It has been somewhat quiet on the Street in terms of other analyst coverage. Its "moderate buy" consensus rating is generated from the two "buys" assigned in the last three months. In addition, the $11 average price target puts the upside potential just under Stanley's forecast at 335%.See the HRVSF stock analysis. Cresco Labs (CRLBF)Source: Shutterstock Cresco Labs (OTCMKTS:CRLBF) is best known for being one of the largest vertically integrated, multi-state cannabis operators in the U.S. Its brands include Cresco, Reserve, Remedi, Mindy's and WellBeings. As one analyst is expecting big things from the company in 2020, CRLBF might not be able to keep a low profile for much longer.On the heels of its latest earnings report, shares slipped when investors learned that CRLBF missed the mark when it came to revenue. It doesn't help that the company posted a net loss of $8.6 million in the third quarter, while reporting net income of $1.2 million in the prior-year quarter.However, Cowen's Vivien Azer still sees a strong long-term growth narrative as the company stands to benefit from its recently received Chicago licenses, ahead of full adult-use legalization in Illinois. "We expect that 2020 will be a transformative year," she said. Bearing this in mind, the five-star analyst decided to stay with the bulls. In addition to the recommendation, her $9.79 price target brings the potential 12-month gain to 77%.Meanwhile, Beacon analyst Russel Stanley highlights its possible acquisition of Tryke as an area to watch. Back in October, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 lapsed, meaning that the acquisition is one step closer to being completed. "We view the development as positive, while also noting that the absence of a second request for information indicates that the DOJ's scrutiny of cannabis M&A may be moderating," Stanley wrote in a note to clients.Similarly, other analysts are optimistic when it comes to CRLBF. With five "buy" ratings issued in the last three months, the consensus is unanimous. The marijuana stock is a "strong buy." Not to mention, the $13 average price target suggests shares could soar 136% in the coming 12 months.See the CRLBF stock analysis. Sundial Growers (SNDL) Source: Shutterstock Sundial Growers (NASDAQ:SNDL) operates facilities throughout Canada and Europe. SNDL expects to hit a worldwide capacity of 95 million grams by the end of 2020.In its most recent quarter, the company was able to deliver net revenue of $33.5 million, a 74% gain on a sequential quarterly basis. On top of this, the amount of cannabis sold increased by about 70% from the second quarter of 2019. Still, its expansion efforts weighed on profits. As a result of its acquisition of United Kingdom-based agricultural indoor producer Bridge Farm in July, SNDL recorded a $97.5 million net loss.Cowen analyst Vivien Azer tells clients that while she is updating her estimates, her bullish thesis remains very much intact. "We continue to favor SNDL given its pricing architecture, modular production grow and CPG-like category management," she noted. To this end, Azer lowered the price target from $15 to $10. Despite cutting the target, she still sees 313% upside potential in store. * 7 Entertainment Stocks to Buy to Escape Holiday Blues When it comes to SNDL, the rest of the Street's take is a mixed bag. Split right down the middle, the consensus is a "moderate buy." While not quite as lofty as Azer's forecast, the $6 average price target indicates huge upside of 126%.See the SNDL stock analysis. Green Thumb Industries (GTBIF)Source: Shutterstock Unlike the other cannabis companies on our list, Green Thumb Industries (OTCMKTS:GTBIF) impressed investors with its most recent quarterly performance.Jumping 296% year-over-year, revenue for its third quarter landed at $68 million. While the company didn't see a profit, it has definitely been making progress. Net loss dropped from $22.2 million in its second quarter to $17.1 million. Adding to the good news, total operating expenses as a percentage of revenue dropped from 72.6% in Q2 to 54% in Q3.The solid performance was driven in part by its Integral Associates acquisition, as it expanded its reach in Nevada and California. Another key factor was that comparable sales for stores open at least 12 months were over 50% more than in the prior-year quarter.All of this has left Cowen's Vivien Azer very excited about GTBIF's future. As such, the five-star analyst maintained her "outperform" rating and $17.50 price target. This implies that shares could rise 88% over the next 12 months.Like Azer, Wall Street likes what it's seeing. Out of the six analysts that have published calls in the last three months, 100% were bullish. Additionally, its $19 average price target lends itself to 102% upside potential.See the GTBIF stock analysis.TipRanks offers investors the latest insight into eight different sectors by tracking the activity of over 5,000 Wall Street analysts. As of this writing, Maya Sasson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Exciting Biotech Stocks to Buy Now * 10 of the Best Stocks to Buy Right Now From the JUST 100 List * 4 Marijuana Stocks to Own If the U.S. Legalizes Pot The post 5 Under-the-Radar Marijuana Stocks With Over 100% Upside appeared first on InvestorPlace.

  • CNW Group

    Harvest Health & Recreation Inc. Announces Two New Appointments to Board of Directors

    PHOENIX , Dec. 3, 2019 /CNW/ -- Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) ("Harvest"), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today announced the appointment of Ana Dutra , CEO of Mandala Global Advisors, and Eula Adams , CEO of Neuromonics Corporation, to its board of directors, effective immediately. "We are pleased to welcome Ana and Eula to the Harvest board after a lengthy process where we evaluated a number of qualified candidates' fit for the demands of the company's board today and into the future," said Harvest CEO Steve White .

  • 3 High-Growth U.S. Cannabis Stocks Poised for Solid Gains

    3 High-Growth U.S. Cannabis Stocks Poised for Solid Gains

    The Q3 earnings reports in the cannabis sector provided the first clear separation between the U.S. and Canadian players. While most of the U.S. multi-state operators (MSOs) shined, the Canadian LPs struggled to grow revenues much less even meet analyst estimates.A big key to the global market forecasts for sales to top $200 billion in the distant future is the substantial market share assigned to the U.S. market in the initial years. For 2020, analysts have forecast U.S. sales topping $16 billion while the total global sales may not even reach $20 billion following the weak recreational sales in Canada.The U.S. cannabis companies aren’t lacking in issues such as a lack of federal approval to limited banking access and unfavorable tax scenarios. The companies don’t lack for growth opportunities with new states opening up their markets on a regular basis including Illinois adding a $2 billion opportunity with the approval of the adult-use market on January 1.The stock market has been just as bad for the U.S. cannabis stocks in 2019 despite strong revenue gains and EBITDA improvements. Several MSOs are now the largest cannabis companies in the world based on revenues once pending mergers are complete while most investors hardly know their names due to the inability of the companies to list their stocks on the major stock exchanges.We’ve delved into these three U.S. cannabis companies that hit the mark during Q3 and poised for continued growth.Stock Comparison Tool | TipRanksCuraleaf (CURLF)Curaleaf reported Q3 pro-forma revenues of $129 million, and for those paying attention, the U.S. MSO now has far more than double the revenues of the large Canadian cannabis LPs.Of course, the reported revenues were only $72 million as the company still works on closing big mergers for Select and Grassroots. Absent any apparent hiccups in closing those deals, Curaleaf is set to claim the position as the leading cannabis company in the world. Despite this fact, the company is hardly a household name.The best part of the Q3 report is the adjusted EBITDA surging to $9 million, up from only $3.4 million in the prior quarter. The company is getting more efficient with cultivation and operations and already generating solid leverage in the system.The results were achieved with gross margins dipping to 47% from 55% last Q3. The big unknown is what the financials look like with the inclusion of Select and Grassroots. These unknowns aren’t helping the stock.The U.S. MSO stocks have generally been held back by the lack of these major deals closing that push the companies up to the largest values in the cannabis sector. Curaleaf has a fully diluted market value of $3 billion based on 464 million shares outstanding. After closing the deals that push the diluted share count to 668 million shares including the 41 million contingent shares, the stock has a market value approaching $4.4 billion.The company guided to 2020 revenues of between $1 billion and $1.2 billion. Additionally, analysts have 2021 revenue targets at $1.6 billion. With this type of growth, Curaleaf remains a stock to own in the sector.Based on the six "buy" and just one "hold" ratings assigned in the last three months, other Wall Street analysts agree that this ‘Strong Buy’ is a solid bet. It also doesn’t hurt that its $12.21 average price target implies 111% upside potential. (See Curaleaf's price targets and analyst ratings on TipRanks)Harvest Health & Recreation (HRVSF)Similar to Curaleaf, Harvest Health & Recreation has pro-forma revenues that now far surpass the depressed levels of the top Canadian players. For Q3, the company saw reported revenues jump 25% sequentially to $33.2 million with pro-forma revenues up at $95.0 million or ~$17.0 million higher than the prior quarter.Harvest Health still struggles on the profit side of the equation with gross margins of only 35% and a reported adjusted EBITDA loss of $10.9 million. The EBITDA loss improved from the prior quarter, but the amount is still nearly a third of revenues.As with most of the MSOs, the company has seen substantial retail location expansion in the recent quarters. Harvest Health probably has one of the largest growth profiles having gone from only 16 locations at the end of June to 26 locations when September closed. The company opened new stores in Arizona, Florida, North Dakota and Pennsylvania along with stores bought in Arizona, California, and Maryland.The company doesn’t need expensive global aspirations with so many opportunities to expand in the U.S. The listed stock valuation is a meager $800 million with the Verano deal amongst others still pending. Analysts estimate 2020 revenues top $700 million making the stock an ultimate bargain.Harvest Health has slipped under most analysts’ radar; the stock’s Moderate Buy consensus is based on just two recent ratings. With shares trading at $2.53 (close match with ACB), the $11.14 average price target suggests room for a 340% upside. (See Harvest Health's price targets and analyst ratings on TipRanks)Trulieve Cannabis (TCNNF)Trulieve Cannabis is the slow and steady play in the U.S. cannabis MSO sector. The company beat analyst estimates with a 22% sequential revenue increase to $70.7 million.Unlike these other picks and most of the major MSOs, Trulieve isn’t relying on a major deal to generate substantial revenue growth. The company generates substantial adjusted EBITDA margins having already reached $36.9 million in Q3 or greater than 50% margins.The company is nearly entirely focused on Florida with 35 dispensaries open after adding six during the quarter. In addition, Trulieve has slowly expanded into California and Connecticut, but the biggest opportunity is when Florida approves recreational cannabis in the state at some point in the future.The stock has a market value of only $1.4 billion while the company kept guidance for 2020 revenues of up to $400 million and adjusted EBTIDA of $160 million. Very few stocks in the cannabis sector have legitimate EBITDA targets while trading at only 9x those estimates.Trulieve is also a Wall Street favorite, earning one of the best analyst consensus ratings in the market. TipRanks analytics exhibit the stock as a Strong Buy. Out of 4 analysts tracked in the last 3 months, three are bullish on the cannabis player while one remains sidelined. With a return potential of 54%, the stock’s consensus target price stands at $18.42. (See Trulieve's stock-price forecast and analyst ratings on TipRanks)